Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.53−0.23 (-2.68%)
Close on Nov 13, 2026Market cap $1.41BP/E –Yield –
Novavax EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Novavax's EPS for the twelve months ending Sep 30, 2026 was -$0.48, down 126.8% year over year. For fiscal 2025 it was $2.58. The highest annual figure on record is $2.58 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.58 | – |
| FY2024 | Dec 31, 2024 | -$1.23 | – |
| FY2023 | Dec 31, 2023 | -$5.41 | – |
| FY2022 | Dec 31, 2022 | -$8.42 | – |
| FY2021 | Dec 31, 2021 | -$23.44 | – |
| FY2020 | Dec 31, 2020 | -$7.27 | – |
| FY2019 | Dec 31, 2019 | -$5.51 | – |
| FY2018 | Dec 31, 2018 | -$9.99 | – |
| FY2017 | Dec 31, 2017 | -$12.56 | – |
| FY2016 | Dec 31, 2016 | -$20.60 | – |
| FY2015 | Dec 31, 2015 | -$12.00 | – |
| FY2014 | Dec 31, 2014 | -$7.40 | – |
| FY2013 | Dec 31, 2013 | -$6.20 | – |
| FY2012 | Dec 31, 2012 | -$4.40 | – |
| FY2011 | Dec 31, 2011 | -$3.40 | – |
| FY2010 | Dec 31, 2010 | -$6.80 | – |
| FY2009 | Dec 31, 2009 | -$9.40 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.19 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.32 | -151.6% |
| Q1 FY2026 | Mar 31, 2026 | -$0.06 | -102.0% |
| Q4 FY2025 | Dec 31, 2025 | $0.09 | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.25 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.62 | -37.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.93 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.51 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.76 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.99 | +70.7% |
| Q1 FY2024 | Mar 31, 2024 | -$1.05 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.44 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.26 | – |
| Q2 FY2023 | Jun 30, 2023 | $0.58 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.41 | -233.2% |
| Q4 FY2022 | Dec 31, 2022 | -$2.28 | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.15 | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.53 | – |
| Q1 FY2022 | Mar 31, 2022 | $2.56 | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.18 | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.31 | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.75 | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.05 | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.70 | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.21 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.30 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.58 | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.13 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.74 | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.69 | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.11 | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.57 | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.33 | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.37 | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.75 | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.20 | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.20 | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.20 | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.20 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?